LitAlert ~~ GeneLit.com

    • Case Report: a BRCA2 Mutation Identified through Next Generation Sequencing in a Birt-Hogg-Dubè Syndrome Family.
    • Bandini E, Cangini I, Arcangeli V, Ravegnani M, Andreotti V, Prisinzano G, Pastorino L, Martinelli G, Falcini F, Calistri D, Zampiga V, Danesi R.
    • Front Oncol. 2022 Jan 19;10:835346. doi: 10.3389/fonc.2022.835346.
    • Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan.
    • Leith A, Ribbands A, Kim J, Last M, Barlow S, Yang L, Ghate SR.
    • Future Oncol. 2022 Jan 19. doi: 10.2217/fon-2021-1113. Epub ahead of print.
    • Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
    • Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Rubio Pérez MJ, Ledermann J, Davidson R, Blakeley C, Bennett J, Barnicle A, Škof E.
    • Gynecol Oncol. 2022 Jan 19:S0090-8258(21)01693-0. doi: 10.1016/j.ygyno.2021.12.025. Epub ahead of print.
    • The neglected members of the family: non-BRCA mutations in the Fanconi anemia/BRCA pathway and reproduction.
    • Vanni VS, Campo G, Cioffi R, Papaleo E, Salonia A, Viganò P, Lambertini M, Candiani M, Meirow D, Orvieto R.
    • Hum Reprod Update. 2022 Jan 19:dmab045. doi: 10.1093/humupd/dmab045. Epub ahead of print.
    • Review
    • Subfertility, use of fertility treatments and BRCA mutation status and the risk of ovarian cancer.
    • Lerner-Geva L, Chetrit A, Farhi A, Lubin F, Sadezki S; National Israel Ovarian Cancer Study Group.
    • Arch Gynecol Obstet. 2022 Jan 18. doi: 10.1007/s00404-021-06355-6. Epub ahead of print.
    • Expression Profiling in Ovarian Cancer Reveals Coordinated Regulation of BRCA1/2 and Homologous Recombination Genes.
    • Custódio N, Savisaar R, Carvalho C, Bak-Gordon P, Ribeiro MI, Tavares J, Nunes PB, Peixoto A, Pinto C, Escudeiro C, Teixeira MR, Carmo-Fonseca M.
    • Biomedicines. 2022 Jan 18;10(2):199. doi: 10.3390/biomedicines10020199.
    • Rare germline copy number variants (CNVs) and breast cancer risk.
    • Dennis J, Tyrer JP, Walker LC, Michailidou K, Dorling L, Bolla MK, Wang Q, Ahearn TU, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Freeman LEB, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bogdanova NV, Bojesen SE, Brenner H, Castelao JE, Chang-Claude J, Chenevix-Trench G, Clarke CL; NBCS Collaborators, Collée JM; CTS Consortium, Couch FJ, Cox A, Cross SS, Czene K, Devilee P, Dörk T, Dossus L, Eliassen AH, Eriksson M, Evans DG, Fasching PA, Figueroa J, Fletcher O, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, García-Closas M, Giles GG, González-Neira A, Guénel P, Hahnen E, Haiman CA, Hall P, Hollestelle A, Hoppe R, Hopper JL, Howell A; ABCTB Investigators; kConFab/AOCS Investigators, Jager A, Jakubowska A, John EM, Johnson N, Jones ME, Jung A, Kaaks R, Keeman R, Khusnutdinova E, Kitahara CM, Ko YD, Kosma VM, Koutros S, Kraft P, Kristensen VN, Kubelka-Sabit K, Kurian AW, Lacey JV, Lambrechts D, Larson NL, Linet M, Ogrodniczak A, Mannermaa A, Manoukian S, Margolin S, Mavroudis D, Milne RL, Muranen TA, Murphy RA, Nevanlinna H, Olson JE, Olsson H, Park-Simon TW, Perou CM, Peterlongo P, Plaseska-Karanfilska D, Pylkäs K, Rennert G, Saloustros E, Sandler DP, Sawyer EJ, Schmidt MK, Schmutzler RK, Shibli R, Smeets A, Soucy P, Southey MC, Swerdlow AJ, Tamimi RM, Taylor JA, Teras LR, Terry MB, Tomlinson I, Troester MA, Truong T, Vachon CM, Wendt C, Winqvist R, Wolk A, Yang XR, Zheng W, Ziogas A, Simard J, Dunning AM, Pharoah PDP, Easton DF.
    • Commun Biol. 2022 Jan 18;5(1):65. doi: 10.1038/s42003-021-02990-6.
    • Clinical benefit with PARP inhibitor for pathogenic germline FANCA-mutated relapsed epithelial ovarian cancer: a case report.
    • Qian B, Lu J, Leng W, Yan Z, Chen S, Yi H, Jiang Z.
    • Front Oncol. 2022 Jan 18;10:778545. doi: 10.3389/fonc.2022.778545.
    • Racial and ethnic variation in multigene panel testing in a cohort of BRCA1/2-negative individuals who had genetic testing in a large urban comprehensive cancer center.
    • Tatineni S, Tarockoff M, Abdallah N, Purrington KS, Assad H, Reagle R, Petrucelli N, Simon MS.
    • Cancer Med. 2022 Jan 17. doi: 10.1002/cam4.4541. Epub ahead of print.
    • Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation.
    • Wei Y, Wei C, Chen L, Liu N, Ou Q, Yin JC, Pang J, Fang Z, Wu X, Wang X, Mu D, Shao Y, Yu J, Yuan S.
    • Cancer Res Treat. 2022 Jan 17. doi: 10.4143/crt.2021.963. Epub ahead of print.
    • Veliparib for the treatment of solid malignancies.
    • George RR, Thomas R, Davice A, Mathew MS.
    • J Oncol Pharm Pract. 2022 Jan 17:10781552221073990. doi: 10.1177/10781552221073990. Epub ahead of print.
    • Review
    • DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy.
    • Zhu S, Zhang Z, Zhang H, Liu Z, Liu M, Liu Q, Zang L, Wang L, Ji J, Wu B, Sun L, Zhang Z, Cao H, Wang Y, Wang H, Shang Z, Niu Y.
    • Prostate. 2022 Jan 17. doi: 10.1002/pros.24292. Epub ahead of print.
    • Germline sequence variants contributing to cancer susceptibility in South African breast cancer patients of African ancestry.
    • Eygelaar D, van Rensburg EJ, Joubert F.
    • Sci Rep. 2022 Jan 17;12(1):802. doi: 10.1038/s41598-022-04791-1.